Clinical ResearchVenous ThromboembolismSurvival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk
Key Words
Abbreviations and Acronyms
Cited by (0)
The RIETE registry was supported by an unrestricted educational grant from Sanofi Spain and by Bayer Pharma AG. (Bayer Pharma AG's support was limited to the part of the RIETE registry outside of Spain, which accounts for approximately 18% to 19% of the total patients.) Dr. Yusen has received grants from Bayer HealthCare Pharmaceuticals, Inc., Portola, Inc., Pfizer, Inc., and Bristol-Myers Squibb; has received consulting fees from Bayer HealthCare, Bristol-Myers Squibb, and GlaxoSmithKline; has served as a legal consultant for Ortho Pharmaceuticals, Inc., Organon, Inc., Pfizer, Portola, and Sanofi-Aventis; and was a member of the Data Safety Monitoring Board for a National Institutes of Health, National Heart, Lung, and Blood Institute–funded trial. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Muriel and Jiménez contributed equally to this work.